March 3, 2021 -- Century Therapeutics has closed $160 million in financing to advance its preclinical pipeline of induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor (CAR)-iT and CAR-i natural killer (NK) cell products.
The preclinical candidates are designed to target hematological and solid tumors. The company's Allo-evasion technology enables the candidates to resist host rejection, enhance cell persistence, and allow repeat dosing to provide durable responses in all patients.
Century anticipates beginning clinical testing of its first off-the-shelf cell therapy products in 2022, as well as the generation of multiple investigational new drug (IND) applications annually in the next years.
The financing was led by Casdin Capital.